$EPIX
ESSA Pharma Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023013733 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.086M $2.814M
YoY Change -24.74% -2.93%
% of Gross Profit
Research & Development $5.226M $6.271M
YoY Change 20.1% -1.93%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.150M $8.912M
YoY Change 0.36% -4.1%
Operating Profit -$7.150M -$8.912M
YoY Change 0.36% -4.1%
Interest Expense $1.668M $1.613M
YoY Change 127.37% 283.45%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.481M -$7.299M
YoY Change -14.22% -17.74%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.481M -$7.299M
YoY Change -13.32% -17.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.12 -$0.17
COMMON SHARES
Basic Shares Outstanding 44.10M 44.09M
Diluted Shares Outstanding 44.09M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.1M $152.5M
YoY Change -11.46% -12.67%
Cash & Equivalents $33.70M $38.47M
Short-Term Investments $114.4M $114.0M
Other Short-Term Assets $585.4K $688.2K
YoY Change -67.76% 20.92%
Inventory
Prepaid Expenses $585.4K $688.2K
Receivables $135.1K $133.3K
Other Receivables $0.00 $0.00
Total Short-Term Assets $148.8M $153.3M
YoY Change -11.99% -12.5%
LONG-TERM ASSETS
Property, Plant & Equipment $68.01K $95.16K
YoY Change -63.53% -56.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $257.2K $264.7K
YoY Change -0.85% 2.0%
Total Long-Term Assets $325.3K $359.8K
YoY Change -27.07% -24.47%
TOTAL ASSETS
Total Short-Term Assets $148.8M $153.3M
Total Long-Term Assets $325.3K $359.8K
Total Assets $149.1M $153.7M
YoY Change -12.03% -12.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.028M $2.051M
YoY Change 112.47% 268.84%
Accrued Expenses $845.7K $769.3K
YoY Change 4.74% -73.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.495M $3.408M
YoY Change 51.28% -15.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.495M $3.408M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.495M $3.408M
YoY Change 46.43% -17.79%
SHAREHOLDERS EQUITY
Retained Earnings -$179.5M -$174.0M
YoY Change 17.39% 18.71%
Common Stock $278.2M $278.1M
YoY Change 0.03% 0.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.6M $150.2M
YoY Change
Total Liabilities & Shareholders Equity $149.1M $153.7M
YoY Change -12.03% -12.53%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.481M -$7.299M
YoY Change -13.32% -17.31%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.492M -$3.324M
YoY Change -42.82% -49.96%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$267.2K -$2.472M
YoY Change -91.0% -78.96%
Cash From Investing Activities -$267.2K -$2.472M
YoY Change -91.0% -78.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -18.16K -35.52K
YoY Change -47.56% -821.95%
NET CHANGE
Cash From Operating Activities -4.492M -3.324M
Cash From Investing Activities -267.2K -2.472M
Cash From Financing Activities -18.16K -35.52K
Net Change In Cash -4.777M -5.832M
YoY Change -56.01% -68.29%
FREE CASH FLOW
Cash From Operating Activities -$4.492M -$3.324M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001633932
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#ShortTermInvestments
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#ShortTermInvestments
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44092374
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44073076
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37410
dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1250703
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
dei City Area Code
CityAreaCode
778
dei Local Phone Number
LocalPhoneNumber
331-0962
dei Security12b Title
Security12bTitle
Common Shares
dei Trading Symbol
TradingSymbol
EPIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44100838
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38466991
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57076475
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
114001923
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
110161029
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
133293
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
6211
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
688172
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1815626
CY2023Q2 us-gaap Assets Current
AssetsCurrent
153290379
CY2022Q3 us-gaap Assets Current
AssetsCurrent
169059341
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
264661
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
95158
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186499
CY2023Q2 us-gaap Assets
Assets
153650198
CY2022Q3 us-gaap Assets
Assets
169505295
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3296377
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2176565
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111273
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
133834
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3407650
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2310399
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76418
CY2023Q2 us-gaap Liabilities
Liabilities
3407650
CY2022Q3 us-gaap Liabilities
Liabilities
2386817
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44092374
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44073076
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
278141528
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
278089136
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48203174
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44043503
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2122144
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2135145
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173980010
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152879016
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
150242548
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153650198
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169505295
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6271186
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6394534
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16096299
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20063752
CY2023Q2 epix Financing Costs
FinancingCosts
1527
CY2022Q2 epix Financing Costs
FinancingCosts
3145
epix Financing Costs
FinancingCosts
5821
epix Financing Costs
FinancingCosts
10996
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2639381
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2895542
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8889192
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9775082
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
8912094
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9293221
us-gaap Operating Expenses
OperatingExpenses
24991312
us-gaap Operating Expenses
OperatingExpenses
29849830
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-827
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
910
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9944
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
30338
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1614048
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
417872
us-gaap Interest And Other Income
InterestAndOtherIncome
3881974
us-gaap Interest And Other Income
InterestAndOtherIncome
974207
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1929
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7298873
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8872510
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21099394
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28824933
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45767
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-45667
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7298873
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8826743
us-gaap Net Income Loss
NetIncomeLoss
-21100994
us-gaap Net Income Loss
NetIncomeLoss
-28779266
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
42689
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2951
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
13001
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-51682
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7256184
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8829694
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21087993
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28830948
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44092374
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44092374
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44059700
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44059700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44085941
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44085941
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44026502
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44026502
us-gaap Profit Loss
ProfitLoss
-21100994
us-gaap Profit Loss
ProfitLoss
-28779266
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91341
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91340
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
482843
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-170331
us-gaap Accretion Expense
AccretionExpense
5821
us-gaap Accretion Expense
AccretionExpense
10555
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
us-gaap Investment Income Net
InvestmentIncomeNet
81350
us-gaap Investment Income Net
InvestmentIncomeNet
124310
CY2022Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50291
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1563608
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
661
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-571
us-gaap Share Based Compensation
ShareBasedCompensation
4161772
us-gaap Share Based Compensation
ShareBasedCompensation
5954444
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
127082
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-469562
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1122248
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1612790
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1118449
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
92390
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15293299
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20521945
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
258307260
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
197959710
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
255044760
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
148254180
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3262500
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49705530
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
319832
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
50291
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
66926
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
104800
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
99384
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-54509
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
287374
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
824
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16827
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18609484
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69956928
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57076475
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137825024
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38466991
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67868096
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104324
CY2021Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27360
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2500091
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9097919
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
187539408
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215508
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1863353
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10903335
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
178714934
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
39566
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1591000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8829694
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
171515806
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6712455
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
162019922
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1437091
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7119354
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
156337659
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1161073
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7256184
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
150242548
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of June 30, 2023, no products are in commercial production or use.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as of the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Estimates and assumptions are reviewed quarterly.</p>
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
113521950
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
44467
CY2023Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
524440
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114001923
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
109833757
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58666
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
385938
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110161029
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114000000.0
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110200000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
44467
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58666
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
179955
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1611516
CY2023Q2 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2022Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
326382
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
22275
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
688172
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1815626
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2050602
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
954598
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
769316
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
807484
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
476459
CY2022Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
414483
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3296377
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2176565
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91340
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
216946
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186499
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
91341
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
95158
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
330970
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
10555
us-gaap Operating Lease Payments
OperatingLeasePayments
99384
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
242141
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
210252
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
5821
us-gaap Operating Lease Payments
OperatingLeasePayments
104800
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
111273
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111273
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.050
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1347500
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.55
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72910
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.41
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
175759
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.60
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7902061
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
51787
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.03
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8150274
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.05
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6058158
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.82
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8150274
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M4D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1297500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.25
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.84
epix Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
307273
epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired
-49.86
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2927477
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.11
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2927477
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 epix Cash Canada Deposit Insurance Corporation Insured Amount
CashCanadaDepositInsuranceCorporationInsuredAmount
100000
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q2 epix Working Capital
WorkingCapital
149882729

Files In Submission

Name View Source Status
0001558370-23-013733-index-headers.html Edgar Link pending
0001558370-23-013733-index.html Edgar Link pending
0001558370-23-013733.txt Edgar Link pending
0001558370-23-013733-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230630.xsd Edgar Link pending
tmb-20230630x10q.htm Edgar Link pending
tmb-20230630x10q001.jpg Edgar Link pending
tmb-20230630xex31d1.htm Edgar Link pending
tmb-20230630xex31d2.htm Edgar Link pending
tmb-20230630xex32d1.htm Edgar Link pending
tmb-20230630_def.xml Edgar Link unprocessable
tmb-20230630_lab.xml Edgar Link unprocessable
tmb-20230630_pre.xml Edgar Link unprocessable
tmb-20230630x10q_htm.xml Edgar Link completed
tmb-20230630_cal.xml Edgar Link unprocessable